Press Releases
Keyword Search
 
2016 | 2015 | 2014
DateTitle 
11/29/16Collegium Announces Underwriters’ Exercise of Option to Purchase Additional Shares
CANTON, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the underwriters for its public offering of 5,000,000 shares of its common stock at $16.00 per share have exercised in full their option to purchase an additional 750,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The closing for the additional purchase of 750,000 shares is expected to take place November 29, 2016, subject to cu... 
Printer Friendly Version
11/21/16Independent Review of Xtampza® ER Published in Peer-Reviewed Medical Journal
CANTON, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that an independent review of Xtampza® ER has been published in the peer-reviewed medical journal, Drugs.  The review is titled “Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain” and highlights data pertaining to the efficacy, safety, abuse-deterrent properties, and alternative modes of administration of Xtampza ER.  For four decades, Drugs has provided a detailed and... 
Printer Friendly Version
11/11/16Collegium to Present at Upcoming Investor Conferences
CANTON, Mass., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in November: The Jefferies London Healthcare Conference on Thursday, November 17th at 12:40 p.m. GMT at the Waldorf Hilton London Hotel The 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30th at 12:00 p.m. EST at the Lotte New York Palace Hotel About Collegium Pharmaceutical, Inc. ... 
Printer Friendly Version
11/10/16Collegium Reports Third Quarter Financial Results and Provides Corporate Update
Broadened Xtampza ER market access with commitments from large commercial payers Submitted Supplemental New Drug Application to the FDA Submitted New Drug Submission to Health Canada CANTON, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the third quarter of 2016 and provided a corporate update.  “It has been a very productive quarter for Collegium.  We have made significant progress on the commercial... 
Printer Friendly Version
11/02/16Collegium to Host Conference Call to Discuss Third Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 10, 2016 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update. Conference Call Information:  To access the conference call, please dial (888)698-6931 (U.S.) or (805)905-2993 (International).  An audio webcast will be accessible from the Inve... 
Printer Friendly Version
10/26/16Collegium Prices Public Offering of $80 million of Common Stock
CANTON, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the pricing of its previously announced public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share.  In addition, Collegium has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock offered in the public offering on the same terms and conditions.  The gross proceeds of this offering are expe... 
Printer Friendly Version
10/25/16Collegium Announces Proposed Public Offering of Common Stock
CANTON, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are being sold by Collegium.  In addition, Collegium has granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. Jefferies LLC and Piper Jaffray & Co. are acting as joint book... 
Printer Friendly Version
10/05/16Collegium Submits Supplemental New Drug Submission to FDA for Xtampza® ER
Comparative data vs OxyContin to support label change CANTON, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) to enhance the label for Xtampza® ER (oxycodone extended-release), an abuse-deterrent, extended-release opioid, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and... 
Printer Friendly Version
10/03/16Collegium Submits New Drug Submission to Health Canada for Xtampza® ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain
CANTON, Mass., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the submission of a New Drug Submission (NDS) to Health Canada seeking marketing approval of Xtampza® ER (oxycodone extended-release), an abuse-deterrent, extended-release opioid, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. “Submitting the NDS in Canada for Xtampza... 
Printer Friendly Version
09/29/16Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
CANTON, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER),” in the peer-reviewed medical journal, The Journal of Clinical Pharmacology. The publication presents the results from a human abuse potential (HAP) study, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration of intact Xtampza® ER (oxycodone extended-release)... 
Printer Friendly Version
09/09/16Review of Xtampza® ER Published in The Journal of the American Medical Association
CANTON, Mass., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of an independent review of Xtampza® ER in The Journal of the American Medical Association (JAMA).  The review titled, “A New Abuse-Deterrent Opioid–Xtampza ER”, was previously published in The Medical Letter.  JAMA is one of the most widely read medical journals in the world and The Medical Letter is widely recognized for its unbiased information about drug therapy... 
Printer Friendly Version
09/07/16Collegium to Present at the BioCentury NewsMakers Conference
CANTON, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 10:30 a.m. Eastern Time.  The conference will be held at Millennium Broadway Hotel, 145 West 44th Street, New York, NY. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on developing a portfolio of produ... 
Printer Friendly Version
09/06/16Collegium Announces the Launch of OpioidIQ
OpioidIQ encourages responsible opioid prescribing and provides educational tools designed to prevent abuse and misuse of opioids CANTON, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announces the launch of OpioidIQ, an online educational tool to assist physicians and other healthcare providers with more effective pain management (Available at: www.OpioidIQ.com). The goal of OpioidIQ is to connect healthcare providers to information and resources aime... 
Printer Friendly Version
09/01/16Collegium Announces Scientific Presentations at PAINWeek 2016 Meeting
CANTON, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at PAINWeek 2016 on September 8th in Las Vegas. The following posters will be presented during the poster session on Thursday, September 8th from 6:30 pm - 8:30 pm PT: The poster titled, “The Effect of Physical Manipulation by Crushing of Xtampza® ER (ox... 
Printer Friendly Version
08/16/16Collegium Announces Publication of Data on Alternative Modes of Administration of Xtampza ER
CANTON, Mass., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “An Abuse-Deterrent, Microsphere-in-Capsule Formulation of Extended-Release Oxycodone: Alternative Modes of Administration to Facilitate Pain Management in Patients with Dysphagia,” in the peer-reviewed medical journal, Current Medical Research and Opinion. The publication included results from multiple in vitro studies and clinical pharmacokinetic studies demonst... 
Printer Friendly Version
08/10/16Collegium Reports Second Quarter Financial Results and Provides Corporate Update
Received FDA approval for Xtampza® ER, Company’s lead opioid analgesic with abuse-deterrent properties Announced U.S. commercial launch of Xtampza ER Reported positive results from a clinical study comparing effect of physical manipulation of Xtampza ER with the abuse-deterrent version of OxyContin® Reported positive results from a clinical study evaluating Hydrocodone DETERx® as a second product candidate Licensed U.S. rights to commercialize ONSOLIS® (fentanyl buccal soluble fil... 
Printer Friendly Version
08/04/16Collegium to Host Conference Call to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 10, 2016 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update. Conference Call Information:  To access the conference call, please dial (888)698-6931 (U.S.) or (805)905-2993 (International).  An audio webcast will be accessible from the Inves... 
Printer Friendly Version
08/01/16Collegium Receives European Patent Allowance Covering Xtampza® ER
CANTON, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL), a specialty pharmaceutical company focused on developing and commercializing innovative abuse-deterrent treatments for chronic pain and other diseases, announced that the European Patent Office has issued an intention to grant letter for European Patent Application No. 05759527.4, an application with claims covering Xtampza® (oxycodone) extended-release (ER) capsules. Xtampza ER is Collegium’s first ... 
Printer Friendly Version
07/06/16Collegium to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
CANTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 8 a.m. Eastern Time.  The conference will be held at Le Parker Meridian New York. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology plat... 
Printer Friendly Version
06/27/16Collegium CEO Michael Heffernan Named EY Entrepreneur of the Year
CANTON, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EY announced that Collegium’s CEO, Michael Heffernan, received the EY Entrepreneur of the Year® 2016 Award in the Life Sciences and Healthcare category in New England. This year marks the 30th anniversary of the EY Entrepreneur of the Year Award program. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesse... 
Printer Friendly Version
06/22/16Collegium Announces Positive Topline Results for Hydrocodone DETERx® Clinical Study
Results demonstrate utility of the DETERx technology platform for hydrocodone as a second abuse-deterrent opioid candidate CANTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from a clinical study evaluating Hydrocodone DETERx® as a second product candidate using its proprietary DETERx drug delivery technology platform. The objective of this pharmacokinetic proof of concept study was to assess two prospective f... 
Printer Friendly Version
06/20/16Collegium Announces Commercial Launch of Xtampza® ER
New Extended-Release Opioid with Abuse-Deterrent Properties CANTON, Mass., June 20, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the commercial launch of Xtampza® ER (oxycodone) extended-release (ER) capsules in the United States. Xtampza ER was approved by the U.S. Food and Drug Administration (FDA) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are in... 
Printer Friendly Version
06/13/16Collegium Announces Election of John A. Fallon, M.D. to Board of Directors
CANTON, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the election of John A. Fallon, M.D. to the Board of Directors. "John’s broad-based payer, managed care and physician group practice management experience will be of great value to Collegium as we launch our first commercial product, Xtampza® ER," said Michael Heffernan, CEO of Collegium. "His experience will provide helpful perspective as we transition to a commercial stage company... 
Printer Friendly Version
06/02/16Collegium Announces Poster Presentations for Xtampza™ ER at the International Conference on Opioids
CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the International Conference on Opioids, which will be held in Boston on June 5-7, 2016. Details of the poster presentations are as follows: Date: Monday, June 6, 2016 Times: 10:00-10:30 am, 12:30-1:30 pm, and 3:30-4:00 pm ET Location: The Jose... 
Printer Friendly Version
06/02/16Collegium to Present at Jefferies and William Blair Conferences
CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: Jefferies Healthcare Conference, New York, June 7th at 10 a.m. ET William Blair Annual Growth Stock Conference, Chicago, June 16th at 10 a.m. CT About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its ... 
Printer Friendly Version
05/23/16Collegium Hosting Investor Day Event on May 25, 2016
CANTON, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) will host Investor Day on Wednesday, May 25th at the St. Regis Hotel in New York City (2 East 55th Street). The meeting will commence at 10:00am ET.  Parties interested in attending the event can Click Here to Register. Webcast Information  A live webcast of the Investor Day event is available here: Click Here for Webcast Access Information Where: WebEx Online Meeting number: 194 922 165 Meet... 
Printer Friendly Version
05/11/16Collegium Licenses the U.S. rights to ONSOLIS® from BioDelivery Sciences
Breakthrough cancer pain product added to the portfolio CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) from BioDelivery Sciences International, Inc. (Nasdaq:BDSI). Collegium expects to launch the product in mid-2017. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pai... 
Printer Friendly Version
05/11/16Collegium Announces Poster Presentations for Xtampza™ ER at American Pain Society Meeting
CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza™ ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, in an elderly population at the American Pain Society Meeting, taking place May 11-14, 2016 in Austin, Texas. The poster titled, “Tolerability, Safety, and Efficacy of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain,”... 
Printer Friendly Version
05/10/16Collegium Reports First Quarter Financial Results and Provides Corporate Update
CANTON, Mass., May 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the first quarter of 2016 and provided a corporate update.  “The beginning of this year marked a major milestone for Collegium as we received FDA approval for our lead product, Xtampza™ ER,” stated Michael Heffernan, Collegium’s CEO. “We are finalizing our launch plans and completing the training of our sales organization, as we prepare for a June launch. Col... 
Printer Friendly Version
05/04/16Collegium Announces Positive Topline Results of Comparative Clinical Trial Evaluating the Effect of Crushing Xtampza™ ER Compared with OxyContin®
CANTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from a comparative clinical trial evaluating the effect of physical manipulation by crushing of Xtampza™ ER (oxycodone extended-release capsules) compared with the abuse-deterrent version of OxyContin® (oxycodone hydrochloride extended-release tablets). Xtampza ER, Collegium’s first FDA approved product utilizing its proprietary DETERx® technology platform, is d... 
Printer Friendly Version
04/27/16Collegium to Host Conference Call to Discuss First Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2016 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update. Conference Call Information:  To access the conference call, please dial (866)864-3220 (U.S.) or (704)908-0478 (International).  An audio webcast will be accessible from the Investor ... 
Printer Friendly Version
04/26/16Collegium Receives FDA Approval for Xtampza™ ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain
CANTON, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) approved Xtampza™ ER (oxycodone) extended-release (ER) capsules CII, a twice-daily, oxycodone medication for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.   Xtampza ER is Collegium’s first product utilizing its proprietary ... 
Printer Friendly Version
04/08/16Collegium to Present at the 15th Annual Needham Healthcare Conference
CANTON, Mass., April 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan, the Company’s CEO, will present at the 15th Annual Needham Healthcare Conference in New York City. The presentation will take place at 1:40 p.m. ET on Wednesday, April 13, 2016 at the Westin Grand Central Hotel. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporat... 
Printer Friendly Version
04/07/16Collegium Announces Publication of Data on the Durability of Pain Relief with Xtampza ER
CANTON, Mass., April 07, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of an analysis of the duration of effect of Xtampza™ ER administered every 12 hours during the Double-blind Maintenance Phase of a multicenter, 12-week clinical study.  The publication is titled, “Evaluation of the Durability of Pain Relief Throughout a 12-Hour Dosing Interval of a Novel, Extended-Release, Abuse-Deterrent Formulation of Oxycodone – Oxycodone DETERx®” a... 
Printer Friendly Version
03/15/16Collegium Reports 2015 Financial Results and Provides Corporate Update
CANTON, Mass., March 15, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its 2015 financial results and provided a corporate update.  “Over the last few months, we made significant progress to advance Xtampza™ ER closer to market launch upon final FDA approval,” stated Michael Heffernan, Collegium’s CEO. “We are very pleased to have recently resolved the Purdue patent litigation that has delayed the potential final approval of Xtampza. As we continue to ... 
Printer Friendly Version
03/10/16Collegium to Host Conference Call to Discuss 2015 Financial Results and Provide Corporate Update
CANTON, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, March 15, 2016 at 7:30 a.m. ET.  The Company will discuss its financial results for 2015 and provide a corporate update.     Conference Call Information:  To access the conference call, please dial (866) 864-3220 (U.S.) or (704) 908-0478 (International).  An audio webcast will be accessible from the In... 
Printer Friendly Version
03/03/16Collegium Announces Publication of Data on the In Vitro Assessment of IV Abuse of Xtampza ER in Journal of Opioid Management
CANTON, Mass., March 03, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from a laboratory-based extraction, injection and syringeability study for Xtampza® ER compared to other marketed opioid analgesics in peer-reviewed Journal of Opioid Management. The publication is titled, “In Vitro Assessment of the Potential for Abuse via the Intravenous Route of Oxycodone DETERx® Microspheres.” Consistent with FDA’s guidance for develo... 
Printer Friendly Version
02/11/16Collegium Announces Favorable Judgment by the District Court of Massachusetts
CANTON, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the District Court of Massachusetts issued an order for final judgment in favor of Collegium and against plaintiffs Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., and Rhodes Technologies. The judgment relates to Purdue’s three Orange Book-listed patents asserted against Collegium that were the cause of the 30 month stay imposed on our New Drug Application ... 
Printer Friendly Version
02/04/16Collegium Announces Issuance of U.S. Patent Covering DETERx®, an Abuse-Deterrent, Extended-Release Technology Platform
Additional Patent Coverage for Lead Product, Xtampza™ ER CANTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that U.S. Patent No. 9,248,195 entitled, "Abuse-deterrent Pharmaceutical Compositions of Opioids and Other Drugs" was issued by the U.S. Patent and Trademark Office (USPTO). The issued patent covers the DETERx technology platform and Collegium's lead product candidate, Xtampza ER (oxycodone) extended-release capsules. The claims... 
Printer Friendly Version
02/02/16Collegium Provides Litigation Update
CANTON, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today provided an update regarding its ongoing litigation with Purdue Pharma L.P. (“Purdue”). On February 1, 2016, the U.S. Court of Appeals for the Federal Circuit rendered its decision to uphold a prior ruling from the U.S. District Court of the Southern District of New York that invalidated four patents associated with OxyContin OP, including Purdue’s three Orange Book-listed patents asserted again... 
Printer Friendly Version
01/25/16Collegium Appoints Ted Schroeder to Board of Directors
CANTON, Mass., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Ted Schroeder to its board of directors. Mr. Schroeder led specialty pharmaceutical company Cadence Pharmaceuticals from its founding until its acquisition by Mallinckrodt Pharmaceuticals for $1.4 billion in 2014. Most recently, Mr. Schroeder co-founded Zavante Therapeutics, which is developing its antibiotic candidate ZTI-01. "Ted has significant experience in th... 
Printer Friendly Version
01/21/16Collegium Announces FDA Acceptance of IND Application for Abuse-Deterrent, Hydrocodone DETERx®
Second Clinical Candidate to Leverage DETERx Technology Platform CANTON, Mass., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application to begin a clinical trial of Hydrocodone DETERx®, an abuse-deterrent, extended-release analgesic for the treatment of chronic pain. This proof of concept clinical trial is intended to evaluate the safety... 
Printer Friendly Version
01/08/16Collegium Pharmaceutical, Inc. Prices Public Offering of $55.0 Million of Common Stock
CANTON, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the pricing of its public offering of 2,750,000 shares of its common stock at a price to the public of $20.00 per share, before underwriting discounts and commissions. The gross proceeds of this offering are expected to be $55.0 million. All of the shares in this offering are being sold by Collegium.  In addition, Collegium has granted the underwriters a 30-day option to purchase from ... 
Printer Friendly Version